Date: 2016-08-03
Type of information: Licensing agreement
Compound: new class of immunomodulatory therapeutics
Company: Philogen (Italy) Janssen Biotech, a J&J company (USA - NJ)
Therapeutic area:
Type agreement: collaboration licensing
Action mechanism:
Disease:
Details: * On August 3, 2016, Philogen announced that they have entered into a collaboration, option and license agreement with Janssen Biotech to discover and develop a new class of immunomodulatory therapeutics. The agreement was facilitated by Johnson & Johnson Innovation.
Financial terms: No financial details of the agreement were released
Latest news:
